Welcome to the Office of Cancer Survivorship Program, DCCPS
The NCI Office of Cancer Survivorship (OCS) works to enhance the quality and length of survival of all persons diagnosed with cancer and to prevent, minimize, or manage adverse effects of cancer and its treatment.
In this recent publication, OCS Deputy Director Dr. Michelle Mollica and coauthors found that financial toxicity among cancer survivors living with metastatic cancer was associated with postponement of medical visits and supportive care services, as well as suboptimal medication adherence. Read more.
March 2024 – Join the NCI Office of Cancer Survivorship for this upcoming OCS Director’s Series webinar. On March 5, 2024, from 2-3 p.m. ET, Dr. Timiya S. Nolan will present Partnership: A Mission and an Imperative for Health Equity-Focused Survivorship Research and Engagement, and Loretta Herring will share her experiences as an advocate. Register now.
April 2024 – Register now for this upcoming OCS Director’s Series webinar. On April 9, 2024, from 2-3 p.m. ET, Dr. John M. Salsman will present Forward-thinking: Progress, Gaps, and Impact in Adolescent and Young Adult Cancer Survivorship, and Dr. Lauren Ghazal will share her experiences as an advocate.
May 2024 – Registration is now open for this May 7, 2024, OCS Director’s Series webinar. Dr. Veena Shankaran MD, MS, will present High-Quality Care Without Breaking the Bank: Strategies to Prevent Financial Hardship in Cancer Survivors.
About The Office of Cancer Survivorship
An individual is considered a cancer survivor from the time of diagnosis, through the balance of life. There are many types of survivors, including those living with cancer and those free of cancer. This term is meant to capture a population of those with a history of cancer rather than to provide a label that may or may not resonate with individuals.
OCS works to promote a better understanding of unique needs of the growing population of cancer survivors, and to enhance our ability to address them.
Featured Graph and Statistic
Researchers at the National Cancer Institute have estimated that 623,405 people in the United States were living with metastatic breast, prostate, lung, colorectal, or bladder cancer or metastatic melanoma as of 2018, and that number is expected to increase to 693,452 by the year 2025.